PI3K
Showing 1 - 25 of >10,000
Endometrial Cancer, Ovarian Cancer Trial in Houston (Copanlisib, fulvestrant)
Recruiting
- Endometrial Cancer
- Ovarian Cancer
-
Houston, TexasM D Anderson Cancer Center
Sep 27, 2022
Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial in Zhoukou, Tianjin (Linperlisib)
Not yet recruiting
- Relapsed/Refractory Large Granular T Lymphocytic Leukemia
-
Zhoukou, Henan, China
- +1 more
Dec 22, 2022
Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment Trial in Zhoukou, Tianjin (Linperlisib)
Not yet recruiting
- Autoimmune Hemolytic Anemia
- Failure of Two Rounds of Treatment
-
Zhoukou, Henan, China
- +1 more
Jan 7, 2023
Hyperglycemia Drug Induced Trial in Durham (REMD-477)
Terminated
- Hyperglycemia Drug Induced
- REMD-477
-
Durham, North CarolinaDuke University Medical Center
Nov 4, 2022
Bile Acids in Acute Insulin Resistance
Recruiting
- PI3K Gene Mutation
- +4 more
- Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
-
New York, New YorkColumbia University Medical Center
Oct 6, 2022
Metastatic Breast Cancer Trial in East Melbourne (BYl719)
Completed
- Metastatic Breast Cancer
-
East Melbourne, Victoria, AustraliaPeter MacCallum Cancer Centre
Aug 11, 2022
Estrogen Receptor-positive Breast Cancer Trial in Nashville (2-Week Ketogenic Diet, Letrozole)
Recruiting
- Estrogen Receptor-positive Breast Cancer
- 2-Week Ketogenic Diet
- Letrozole
-
Nashville, TennesseeVanderbilt-Ingram Cancer Center
Sep 20, 2022
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +
Not yet recruiting
- Breast Cancer
- +3 more
- AI+CDK4/6i
- +7 more
-
Miami, FloridaUniversity of Miami
Apr 12, 2023
Leukemia, Acute Lymphocytic Trial in Durham (Copanlisib)
Recruiting
- Leukemia, Acute Lymphocytic
-
Durham, North CarolinaDuke Cancer Center
Jun 28, 2022
Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)
Recruiting
- Lung Cancer Squamous Cell
- +3 more
-
Boston, Massachusetts
- +2 more
Jan 9, 2023
Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)
Not yet recruiting
- Metastatic Breast Cancer
- +3 more
- OP-1250
- +2 more
- (no location specified)
Aug 18, 2022
Melanoma and Other Malignant Tumors of Skin, Metastatic Melanoma Trial in Houston (GSK2636771, Pembrolizumab)
Active, not recruiting
- Melanoma and Other Malignant Neoplasms of Skin
- Metastatic Melanoma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 22, 2022
HER2-positive Breast Cancer Trial (Inavolisib, PHESGO, Endocrine therapy)
Not yet recruiting
- HER2-positive Breast Cancer
- Inavolisib
- +2 more
- (no location specified)
Mar 23, 2022
PIK3CA Mutation-Related Tumors Trial in Shanghai (WX390)
Completed
- PIK3CA Mutation-Related Tumors
-
Shanghai, Shanghai, ChinaShanghai East Hospital
Nov 9, 2023
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +5 more
- PI3K inhibitor BYL719
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 14, 2022
Everolimus-containing Chemotherapy in HER2- mBC PI3K/AKT/mTOR
Completed
- Breast Cancer
- +2 more
- No intervention, it was a retrospective study.
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 13, 2021
Locally Advanced Breast Cancer, Metastatic Breast Cancer Trial in Batumi, Tbilisi (Tenalisib)
Active, not recruiting
- Locally Advanced Breast Cancer
- Metastatic Breast Cancer
-
Batumi, Georgia
- +2 more
May 2, 2022
Locally Advanced Malignant Solid Tumor, Metastatic Malignant Tumor in the Bone, Metastatic Malignant Solid Tumor Trial
Withdrawn
- Locally Advanced Malignant Solid Neoplasm
- +3 more
- (no location specified)
May 24, 2022
Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of
Not yet recruiting
- Triple Negative Breast Cancer
- +2 more
- Everolimus
- Investigator's Choice of Chemotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 25, 2023
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (TGR-1202, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
-
Monterey, California
- +4 more
Aug 29, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,
Completed
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +8 more
- PI3K inhibitor BKM120
- +3 more
-
Atlanta, Georgia
- +1 more
Jun 27, 2022
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,
Recruiting
- Deleterious BRCA1 Gene Mutation
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Aug 23, 2022
Breast Cancer, PI3K, Alpelisib Trial in France (Alpelisib, Chemotherapy)
Active, not recruiting
- Breast Cancer, PI3K, Alpelisib
-
Angers, France
- +13 more
Mar 8, 2022